Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.71 -0.1%	$18.02	$13.40 ▼ $25.23	$3.63B	0.65	1.94 million shs	1.15 million shs
GMAB Genmab A/S	$22.82 -1.2%	$20.56	$17.24 ▼ $28.56	$14.63B	0.96	1.17 million shs	1.11 million shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.58 million shs	N/A
RDY Dr. Reddy's Laboratories	$15.80 -2.3%	$14.17	$12.26 ▼ $16.89	$13.19B	0.33	1.51 million shs	1.69 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-1.23%	+23.35%	+24.06%	+41.25%
GMAB Genmab A/S	0.00%	+2.79%	+16.13%	+11.26%	-14.76%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+0.46%	+93.36%
RDY Dr. Reddy's Laboratories	0.00%	+1.66%	+9.78%	+24.45%	+10.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.3849 of 5 stars	3.3	1.0	0.0	0.0	3.9	4.2	1.3
GMAB Genmab A/S	3.8294 of 5 stars	3.3	5.0	0.0	0.0	2.4	0.0	3.1
ITCI Intra-Cellular Therapies	0.869 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
RDY Dr. Reddy's Laboratories	1.3454 of 5 stars	1.5	3.0	1.7	0.0	2.5	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	23.38% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	71.63% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	7.29% Upside

Current Analyst Ratings Breakdown

Latest ACAD, GMAB, ITCI, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	RDY Dr. Reddy's Laboratories	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$14.44 ➝ $16.90
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.65	N/A	N/A	$2.63 per share	8.25
GMAB Genmab A/S	$3.12B	4.70	$1.54 per share	14.80	$8.04 per share	2.84
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
RDY Dr. Reddy's Laboratories	$325.54B	0.04	$1.19 per share	13.25	$4.50 per share	3.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.83	28.57	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	13.11	12.82	2.65	36.30%	16.78%	13.79%	8/14/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
RDY Dr. Reddy's Laboratories	$668M	$0.66	25.16	19.27	N/A	17.25%	17.87%	12.32%	7/25/2025 (Estimated)

Latest ACAD, GMAB, ITCI, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	$0.22	+$0.02	$0.22	$83.70 billion	$996.17 million
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.51%	N/A	12.12%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
GMAB Genmab A/S	N/A	5.25	5.24
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
RDY Dr. Reddy's Laboratories	0.02	1.92	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
GMAB Genmab A/S	1,660	641.22 million	651.58 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
RDY Dr. Reddy's Laboratories	24,800	834.77 million	818.05 million	Optionable

ACAD, GMAB, ITCI, and RDY Headlines

Recent News About These Companies

Rhumbline Advisers Sells 86,773 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

June 14 at 3:20 AM | marketbeat.com

Stanley Laman Group Ltd. Makes New $1.85 Million Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)

June 13 at 8:41 AM | marketbeat.com

Dr. Reddy's Laboratories rallies Tuesday, outperforms competitors

June 10, 2025 | marketwatch.com

Dr. Reddy's Laboratories Reaches Analyst Target Price

June 8, 2025 | nasdaq.com

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded at Hsbc Global Res

June 7, 2025 | americanbankingnews.com

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded to "Buy" at HSBC

June 7, 2025 | americanbankingnews.com

HSBC Upgrades Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY)

June 6, 2025 | msn.com

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded by Hsbc Global Res to "Strong-Buy" Rating

June 6, 2025 | marketbeat.com

HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold

June 5, 2025 | msn.com

Dr. Reddy's Laboratories rallies Thursday, outperforms competitors

June 5, 2025 | marketwatch.com

HSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings rebound

June 5, 2025 | in.investing.com

Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech

June 5, 2025 | investing.com

Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Time to Buy?

June 5, 2025 | marketbeat.com

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

June 5, 2025 | zacks.com

Dr. Reddy's Laboratories (NYSE:RDY) Raised to "Buy" at HSBC

June 5, 2025 | marketbeat.com

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 5, 2025 | businesswire.com

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 5, 2025 | finance.yahoo.com

Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)

June 5, 2025 | msn.com

Dr. Reddy’s Labs ADR Stock Price History

June 4, 2025 | investing.com

Dr. Reddy's Laboratories rises Wednesday, underperforms market

June 4, 2025 | marketwatch.com

Two Sigma Advisers LP Acquires 23,700 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD, GMAB, ITCI, and RDY Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.71 -0.03 (-0.14%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.68 -0.03 (-0.14%)

As of 06/13/2025 04:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Genmab A/S NASDAQ:GMAB

$22.82 -0.27 (-1.17%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$22.81 -0.01 (-0.04%)

As of 06/13/2025 06:58 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Dr. Reddy's Laboratories NYSE:RDY

$15.80 -0.37 (-2.30%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$15.78 -0.01 (-0.08%)

As of 06/13/2025 05:04 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time